NCT02665273

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Montefiore Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.

Detailed description

The investigators are testing the following hypothesis: In a population of patients who present to an ED with acute migraine and have been treated with parenteral metoclopramide unsuccessfully, bilateral greater occipital nerve blocks with bupivicaine will provide greater rates of short-term and sustained headache freedom than bupivacaine injected intradermally.

Conditions

• Migraine

Interventions

Type	Name	Description
PROCEDURE	Greater occipital nerve block	Bilateral greater occipital nerve block
DRUG	Bupivacaine	0.5 cc of 0.5% bupivacaine injected intradermally

Timeline

• Start date: 2015-07-01
• Primary completion: 2018-01-01
• Completion: 2018-01-01
• First posted: 2016-01-27
• Last updated: 2020-08-11
• Results posted: 2020-08-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study